期刊
PSYCHIATRIC CLINICS OF NORTH AMERICA
卷 37, 期 3, 页码 375-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.psc.2014.05.006
关键词
Obsessive-compulsive disorder; OCD; Pharmacotherapy a SSRI; Antidepressant; Augmentation
类别
资金
- NCATS NIH HHS [UL1 TR000142] Funding Source: Medline
- NIMH NIH HHS [R01 MH095790, K23 MH091240, R34 MH083115, R25 MH077823] Funding Source: Medline
Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population over the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据